Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

Phase 2 Completed 10 enrolled University of Colorado, Denver

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and efficacy of combined treatment with Ipilimumab and all-trans retinoic acid (ATRA) in melanoma patients.

Timeline

Start: 2015-12-17
Primary completion: 2018-08
Completion: 2023-01-18

Publications

Results Tobin RP, Jordan KR, Robinson WA, Davis D, Borges VF, Gonzalez R, Lewis KD, McCarter MD. Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab. Int Immunopharmacol. 2018 Oct;63:282-291. doi: 10.1016/j.intimp.2018.08.007. Epub 2018 Aug 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ipilimumab	Monoclonal antibody	3 mg/kg	—
Subject	Ipilimumab	Monoclonal antibody	10 mg/kg	—
Subject	Tretinoin	Small molecule	150 mg/m2	Oral

Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

Summary

Timeline

Publications

Drugs

Indications